Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 15, 2024
- Pharmaceuticals
- R&D
Roche Announces New Two-Year Data of Evrysdi for Children with Spinal Muscular Atrophy (SMA)
TOKYO, October 15, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on October 14, regarding two-year data from the RAINBOWFISH study of Evrysdi® (generic name: risdiplam) for pre-symptomatic spinal muscular atrophy (from birth to 6 weeks of age at first dose).
Please refer to the link below for details of the press release:
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
https://www.roche.com/media/releases/med-cor-2024-10-14
